| CPC A61M 1/3679 (2013.01) [A61K 33/44 (2013.01); A61M 1/3486 (2014.02); B01D 15/00 (2013.01); B01J 20/20 (2013.01); B01J 20/265 (2013.01); B01J 20/28016 (2013.01); B01J 20/28052 (2013.01); B01J 20/28092 (2013.01); B01J 20/3204 (2013.01); B01J 20/321 (2013.01); B01J 20/3212 (2013.01); B01J 20/3242 (2013.01); B01J 20/3293 (2013.01)] | 8 Claims |
|
1. A device for use during extracorporeal treatment of preeclampsia comprising:
a first component comprising a bimodal synthetic carbon particle mixture and a first portion of whole blood, wherein the bimodal synthetic carbon particle mixture is present in the device prior to the extracorporeal treatment and wherein the first portion of whole blood is not present in the device prior to the extracorporeal treatment, and wherein a synthetic carbon particle of the bimodal synthetic carbon particle mixture is functionalized with one or more antibodies, anti-antibodies, anti-cytokines, synthetic ligands, or combinations thereof to enhance the affinity of the synthetic carbon particle for molecules to be removed from the first portion of whole blood;
a second component comprising a first resin bead covalently functionalized with at least one affinity ligand directed toward syncytiotrophoblast-derived factor sEndoglin and a second portion of whole blood, wherein the least one affinity ligand directed toward syncytiotrophoblast-derived factor sEndoglin is covalently bonded to the first resin bead, wherein the first resin bead is present in the device prior to the extracorporeal treatment and wherein the second portion of whole blood is not present in the device prior to the extracorporeal treatment; and
a third component comprising a second resin bead functionalized with at least one affinity ligand directed toward syncytiotrophoblast-derived factor soluble Fms-like tyrosine kinase-1 and a third portion of whole blood, wherein the least one affinity ligand directed toward syncytiotrophoblast-derived factor soluble Fms-like tyrosine kinase-1 is covalently bonded to the second resin bead, wherein the device comprises at least one column and the first component, the second component, and the third component are each disposed in one or more columns, wherein the second resin bead is present in the device prior to the extracorporeal treatment and wherein the third portion of whole blood is not present in the device prior to the extracorporeal treatment, wherein the device is configured to treat preeclampsia when the first and second resin beads have a particle size of from about 1 mm to about 12 mm, and wherein the first resin bead, the second resin bead, or both the first resin bead and the second resin bead comprises gelatin, collagen type I, fibrin glue, polyglycerol sebacate (PGS), polyglycolic acid (PGA), poly-1-lactide (PLA), poly(lactide-co-glycolide) (PLGA), polyvinyl alcohol (PVA), polycaprolactone, poly(N-isopropylacrylamide), sepharose, polyoxymethylene (POM), polyvinylchloride (PVC), polyvinylidene chloride (PVDC), polystyrene (PS), polyacrylate, polyacrylamide, polyglycidyl methacrylate (PGMA), acrylonitrile butadiene styrene (ABS), polyacrylonitrile (PAN), polyester, polycarbonate, polyethylene terephthalate (PET), polyamide, polyaramide, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP), polysulfone (PS), polyethersulfone (PES), polyarylethersulfone (PEAS), ethylene vinyl acetate (EVA), ethylene vinyl alcohol (EVOH), polyamide-imide, polyaryletherketone (PAEK), polybutadiene (PBD), polybutylene (PB), polybutylene terephthalate (PBT), polyhydroxyalkanoate, polyether ether ketone (PEEK), polyether ketone ketone (PEKK), polyether imide (PEI), polyimide, polylactic acid (PLA), polymethyl pentene (PMP), poly(p-phenylene ether) (PPE), styrene acrylonitrile (SAN), polybutenoic acid, poly(4-allyl-benzoic acid), poly(glycidyl acrylate), polyglycidyl methacrylate (PGMA), poly(allyl glycidyl ether), poly(vinyl glycidyl ether), poly(vinyl glycidyl urethane), polyallylamine, polyvinylamine, copolymers of said polymers; derivatives of said polymers, or combinations thereof.
|